← Zhejiang Yatai Pharmaceutical overview

Zhejiang Yatai Pharmaceutical vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Zhejiang Yatai Pharmaceutical Co Ltd (002370.CS)

Q3 2026
▲2

Buyback and pipeline progress offset by weak reported profit

  • Buyback plan and first tranche completed The chairman proposed a 10-20 million yuan buyback for equity incentives, and the company then completed a first tranche of about 3.34 million shares for roughly 20 million yuan. Buying its own stock signals confidence and supports the share price.

    This is the main capital action driving the stock and shows management's confidence.

  • Spironolactone tablets pass consistency review Yatai's spironolactone tablets passed China's generic drug quality and efficacy consistency evaluation. This enriches its product pipeline and makes the drug more competitive in hospital procurement, supporting future sales.

    It is a concrete regulatory win that improves the product pipeline and competitiveness.

  • H1 underlying profit turns positive but reported net loss First-half revenue rose 3.6% to 158 million yuan, and non-recurring net profit swung to a 1.4 million yuan gain from a big loss, helped by lower financial expenses and more high-margin non-antibiotic products. But reported net profit was a 440,000 yuan loss, down 100.4% year on year.

    It shows the core business improving while the headline reported profit still disappoints, a key counterweight.

August 2026
▲2

Buyback and pipeline progress offset by weak reported profit

  • Buyback plan and first tranche completed The chairman proposed a 10-20 million yuan buyback for equity incentives, and the company then completed a first tranche of about 3.34 million shares for roughly 20 million yuan. Buying its own stock signals confidence and supports the share price.

    This is the main capital action driving the stock and shows management's confidence.

  • Spironolactone tablets pass consistency review Yatai's spironolactone tablets passed China's generic drug quality and efficacy consistency evaluation. This enriches its product pipeline and makes the drug more competitive in hospital procurement, supporting future sales.

    It is a concrete regulatory win that improves the product pipeline and competitiveness.

  • H1 underlying profit turns positive but reported net loss First-half revenue rose 3.6% to 158 million yuan, and non-recurring net profit swung to a 1.4 million yuan gain from a big loss, helped by lower financial expenses and more high-margin non-antibiotic products. But reported net profit was a 440,000 yuan loss, down 100.4% year on year.

    It shows the core business improving while the headline reported profit still disappoints, a key counterweight.

Latest
▲2

Buyback and pipeline progress offset by weak reported profit

  • Buyback plan and first tranche completed The chairman proposed a 10-20 million yuan buyback for equity incentives, and the company then completed a first tranche of about 3.34 million shares for roughly 20 million yuan. Buying its own stock signals confidence and supports the share price.

    This is the main capital action driving the stock and shows management's confidence.

  • Spironolactone tablets pass consistency review Yatai's spironolactone tablets passed China's generic drug quality and efficacy consistency evaluation. This enriches its product pipeline and makes the drug more competitive in hospital procurement, supporting future sales.

    It is a concrete regulatory win that improves the product pipeline and competitiveness.

  • H1 underlying profit turns positive but reported net loss First-half revenue rose 3.6% to 158 million yuan, and non-recurring net profit swung to a 1.4 million yuan gain from a big loss, helped by lower financial expenses and more high-margin non-antibiotic products. But reported net profit was a 440,000 yuan loss, down 100.4% year on year.

    It shows the core business improving while the headline reported profit still disappoints, a key counterweight.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

September 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

Latest
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.